ArticleIntegrative cancer therapies
A Retrospective Assessment of Symptom Reduction With Group Acupuncture at an NCI-Designated Comprehensive Cancer Center.
Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acupuncture is increasingly integrated into oncology care as a nonpharmacologic strategy for managing cancer- and treatment-related symptoms. However, specific symptom responses remain incompletely characterized. This study retrospectively evaluated changes in individual symptoms following completion of a structured group acupuncture regimen at an NCI-designated comprehensive cancer center. Patients treated at our Integrative Oncology and Survivorship Program between 2023 and 2025 who completed ≥8 acupuncture sessions and pre- and post-treatment Measure Yourself Concerns and Wellbeing (MYCaW) questionnaires were included. Patients identified and rated their two most bothersome symptoms on a 0-6 Likert scale. Symptoms were categorized into 20 domains. Pre-to-post changes were assessed using Wilcoxon signed-rank tests. Among 723 patients (median age 60 years; 78.8% female; 36.0% Black), breast cancer was the most common diagnosis (52.8%). Reported symptoms included peripheral neuropathy (n=293), generalized pain (n=245), fatigue (n=120), hot flashes (n=96), and insomnia (n=83), with a median severity score of 5. Significant improvements were observed across all domains (p<0.05) except depression and urinary incontinence (p = 0.057). Large effect sizes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.